Director Brian Cherry Buys $1M of Atara Stock at $9.60
ATRA has more than doubled off its 52-week low of $3.92 on elevated volume (2.0× avg).
Summary
Director Brian Cherry bought $1M of Atara stock at $9.60 per share, increasing his holdings to 166,486 shares. The purchase was made from the company under its existing sales agreement.
Key Events · Ownership and Investor Activity · ATRA
-
Director Buys $1M in Stock
Brian Cherry purchased 104,166 shares at $9.60 for $999,993.60 on September 4, 2026, increasing his direct holdings to 166,486 shares.
-
Purchase from Issuer
The shares were acquired from Atara through its sales agent under the Sales Agreement dated November 1, 2023 with TD Securities (USA) LLC.
-
Capital Infusion
The $1M purchase provides cash to Atara, which reported only $9.9M in cash and a going concern risk in its latest 10-Q.
-
Director Confidence
The open-market purchase by a director signals confidence in the company's prospects despite its financial challenges.
Analysis · ATRA · Life Sciences
On September 4, 2026, Director Brian Cherry purchased 104,166 shares at $9.60 for $999,993.60, increasing his direct holdings to 166,486 shares. The purchase was made from the Issuer through its sales agent under the Sales Agreement dated November 1, 2023 with TD Securities (USA) LLC. This is a significant open-market purchase by a director, representing over 1% of the company's market cap, and comes at a time when Atara has only $9.9M in cash and a going concern risk. The purchase provides capital to the company and signals director confidence, though it is also dilutive to existing shareholders.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATRA was trading at $9.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.